Markets

final.Georgia Power has reached a stipulated agreement with the Georgia Public Service Commission that, if approved, will keep residential rates frozen through 2028 and deliver about $102 annual savings per typical household. The deal shifts $556 million in incremental revenue from large‑load customers into new resources, including 3,600 MW of combined‑cycle gas, over 3,000 MW of battery storage, 350 MW of solar‑paired storage, and 2,800 MW of PPAs. The strategy aims to meet rising demand while supporting clean‑energy goals and protecting small‑consumer rates.

.Nexus Uranium Corp. has added Jon Winter to its advisory board, effective Dec 1 2025. Winter brings over 40 years of experience in environmental permitting, regulatory affairs, and in‑situ uranium operations across North and Central America, including work on enCore Energy’s Dewey‑Burdock project. He will help accelerate Nexus’s U.S. uranium projects through permits and development. In connection with his appointment, Winter received 30,000 restricted share units that vest over 12 months.

.

CathVision announced Eric Thepaut, former Boston Scientific EMEA President, as independent Chairman of the Board and launched ECGenius® System version 3.5. The upgraded system adds flexible interfacing, DICOM archiving, improved hardware for lower artefacts, and 12‑lead ECG capture, enhancing workflow and signal fidelity. With FDA clearance (2023) and CE marking (2025), the company aims to accelerate U.S. and European EP market entry, leveraging Thepaut’s experience to capture a growing $10 billion market and target $120 million in revenue within three years.

Nordex Group secured contracts from Alliant Energy to supply up to 190 N133 and N163 Delta4000 turbines, providing as much as 1,060 MW of capacity for Midwest wind farms. Production will resume at Nordex’s West Branch, Iowa facility, creating local jobs and marking the company’s largest U.S. volume award in its 25‑year history. The agreements are conditional on regulatory approvals and installations are slated for 2028‑2029.

.Terns Pharmaceuticals (NASDAQ: TERN) priced an upsized underwritten public offering of 16,250,000 common shares at $40.00 each, generating about $650 million in gross proceeds. Underwriters have a 30‑day option to purchase an additional 2,437,500 shares. The transaction is expected to close on December 11, 2025. Net proceeds will fund research, clinical trials, development, and manufacturing of the lead candidate TERN‑701, support initial launch activities, and cover working‑capital and general corporate needs.

Dyne Therapeutics announced the pricing of an upsized underwritten public offering of 18,980,478 common shares at $18.44 per share, targeting $350 million in gross proceeds before fees. All shares are being sold by the company, with a 30‑day overallotment option for underwriters to purchase up to an additional 2,847,071 shares. The offering is expected to close on or about December 11, 2025, subject to customary conditions. Morgan Stanley, Jefferies, Stifel and Guggenheim Securities serve as joint book‑running managers.

Aero Energy agreed on Dec 9, 2025 to sell 100 % of RIO Explorations SpA, which holds Chile’s Dorado and Cordillera gold projects, to Batik Resources for $3.6 million. Payment consists of $700,000 cash at closing (≈Dec 17, 2025) net of Chilean withholding tax and $2.9 million in Batik shares issued when Batik completes a public listing by Oct 31, 2026; if the listing fails, Aero can demand the RIO shares back at no cost. Aero also plans a 1‑for‑10 share consolidation and has issued 295,750 finder warrants at $0.11, exercisable until Nov 14, 2026.

BNY Mellon’s High Yield Strategies Fund (NYSE: DHF) declared a monthly cash dividend of $0.0175 per share, payable January 9 2026, with the ex‑dividend date of December 23 2025. The fund, managed by BNY Mellon Investment Adviser, targets income from high‑yield fixed‑income securities—including corporate, emerging‑market, and asset‑backed bonds—while employing dynamic duration and credit risk management. Analysts view the steady dividend as a sign of confidence amid broader fixed‑income payout cuts. As a closed‑end fund, its market price may trade at a premium or discount to NAV, affecting total return.

Eli Lilly will turn Huntsville, Alabama into the domestic hub for small‑molecule and peptide API production, investing more than $6 billion in a next‑generation facility that will manufacture its first oral GLP‑1 agonist, orforglipron. Construction begins in 2026, creating about 3,000 temporary jobs, and the plant—set to finish in 2032—will support 450 high‑skill positions. The site employs AI‑driven automation, aims for carbon‑neutral operations, and complements Lilly’s broader U.S. expansion to bolster supply‑chain resilience and domestic drug manufacturing.

Microsoft’s 2025 annual meeting saw shareholders reject Proposal 9—a BDS‑linked resolution targeting Israel—by over 70% of votes. JLens and the ADL praised the outcome, noting the proposal’s political motive contrary to fiduciary duty. More than 50 shareholders co‑filed the measure, with Norway’s GPFG voting for it, while proxy advisors were split (Glass Lewis against, ISS for). The defeat highlights growing resistance to overtly political ESG proposals and signals firms will scrutinize activist demands for governance and reputational risk.